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Background
The influence of preexisting immunity to viral vectors is a
major issue for the development of viral vectored vac-
cines. Here we report that for a DNA/MVA vaccine, preex-
isting immunity to vaccinia virus (Dryvax) decreases
cellular immune responses but enhances control of an
intrarectal SIV challenge.
Methods
Three groups of rhesus macaques, eight per group, were
studied. The Dryvax-naive and Dryvax-immune groups
received the DNA/MVA SIV vaccine (DNA at weeks 0 and
8, and rMVA at weeks 16 and 24). In addition, the Dryvax-
immune group received the Dryvax vaccine 1.5 years prior
to the DNA prime. The control group did not receive any
vaccine. All macaques were challenged intrarectally with
SIV251 at 9 months after the final MVA.
Results
Following vaccination, the frequency of SIV Gag-specific
CD4 and CD8 T cells were 510 fold lower in the Dryvax-
immune group than the Dryvax-naive group. Despite their
low SIV-specific T cell responses, the Dryvax-immune
macaques exhibited the best control of SIV challenge with
viremia 480-fold lower at peak and 40-fold lower at set
point than in the unvaccinated control animals (p = 0.01).
The enhanced control in the Dryvax-immune animals was
not restricted to Mamu A*01+ animals and was strongly
associated with reduced colorectal virus at 2 weeks post
challenge. Factors that correlated with early colorectal
viral control included the magnitude of vaccine-elicited
CD4 T cells displaying the CCR5 viral co-receptor, which
was dampened in the Dryvax-immune animals; the pres-
ence of anti-viral mucosal IgA, which was more frequent
in the Dryvax-immune animals, and the avidity of the
anti-Env Ab response. The frequency of anti-viral CD8 T
cells did not correlate with early colorectal viral control.
Conclusion
These results highlight important roles for vaccine-elicited
CCR5+ CD4 T cells in augmenting, and mucosal IgA and
high avidity anti-Env IgG in restricting the early replica-
tion of a colorectal immunodeficiency virus challenge.
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